- Home
- CODX vs VYNE Comparison
CODX vs VYNE Comparison
Compare CODX & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODX
- VYNE
- Stock Information
- Founded
- CODX 2013
- VYNE 2003
- Country
- CODX United States
- VYNE United States
- Employees
- CODX N/A
- VYNE N/A
- Industry
- CODX Medical/Dental Instruments
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- CODX Health Care
- VYNE Health Care
- Exchange
- CODX Nasdaq
- VYNE Nasdaq
- Market Cap
- CODX 9.8M
- VYNE 7.9M
- IPO Year
- CODX 2017
- VYNE 2018
- Fundamental
- Price
- CODX $0.42
- VYNE $0.30
- Analyst Decision
- CODX Buy
- VYNE Buy
- Analyst Count
- CODX 2
- VYNE 2
- Target Price
- CODX $5.50
- VYNE $8.00
- AVG Volume (30 Days)
- CODX 13.6M
- VYNE 1.7M
- Earning Date
- CODX 11-06-2025
- VYNE 11-06-2025
- Dividend Yield
- CODX N/A
- VYNE N/A
- EPS Growth
- CODX N/A
- VYNE N/A
- EPS
- CODX N/A
- VYNE N/A
- Revenue
- CODX $1,003,653.00
- VYNE $476,000.00
- Revenue This Year
- CODX N/A
- VYNE N/A
- Revenue Next Year
- CODX $31.58
- VYNE N/A
- P/E Ratio
- CODX N/A
- VYNE N/A
- Revenue Growth
- CODX N/A
- VYNE N/A
- 52 Week Low
- CODX $0.23
- VYNE $0.28
- 52 Week High
- CODX $1.40
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- CODX 56.81
- VYNE 32.11
- Support Level
- CODX $0.30
- VYNE $0.30
- Resistance Level
- CODX $0.72
- VYNE $0.33
- Average True Range (ATR)
- CODX 0.06
- VYNE 0.02
- MACD
- CODX 0.02
- VYNE 0.02
- Stochastic Oscillator
- CODX 28.32
- VYNE 39.83
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.